News All PostNewsAcousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio14 May 2018read more >Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases24 April 2018read more >AXXAM expands its natural products service business22 March 2018read more >Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain…10 January 2018read more >Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round4 January 2018read more >leadXpro and Axxam enter collaboration on a GPCR lead discovery project1 November 2017read more >Load MoreEnd of Content.
Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio14 May 2018read more >
Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases24 April 2018read more >
Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain…10 January 2018read more >
Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round4 January 2018read more >
